SMA Newsroom

Please find the letter here

Community Letter from NMD Pharma: completion of its Phase 2 SYNAPSE-SMA clinical trial of ignaseclant (formerly NMD670)

Community letter Scholar Rock

FDA accepts to review Biologics License Application for apitegromab

FDA accepts to review Biologics License Application for apitegromab

Community Update: FDA accepts to review Biologics License Application for apitegromab

SMA Europe letter

Community update: Novartis receives EMA CHMP positive opinion for Itvisma

CHMP summary of opinion

Novartis press release

Novartis receives EMA CHMP positive opinion for Itvisma, gene therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA).

Community Update: Novartis receives EMA CHMP positive opinion for Itvisma

Full publication

We are delighted to invite you to read the latest "A seat, a voice, a vote: reimagining the role of SMA patient advocates in research and care&rdquo; by Rare Revolution Magazine.&nbsp;

New publication: A seat, a voice, a vote: reimagining the role of SMA patient advocates in research and care by Rare Revolution Magazine.

Categories